MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability

Oncogene

Volumn 34, Issue 2, 2015, Pages 237-245

  Wan, C ^a   Hou, S ^a   Ni, R ^a   Lv, L ^a   Ding, Z ^a   Huang, X ^a   Hang, Q ^a   He, S ^a   Wang, Y ^a   Cheng, C ^a   Gu, X X ^a   Xu, G ^a   Shen, A ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

cell cycle regulation; hepatocellular carcinoma; MIF4GD; p27

Indexed keywords

CARRIER PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; SLIP1 PROTEIN, HUMAN;

ADULT; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOGENESIS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HEPG2 CELL LINE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MIDDLE AGED; MOUSE; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE; XENOGRAFT; YOUNG ADULT;

ADULT; AGED; ANIMALS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HEP G2 CELLS; HETEROGRAFTS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; YOUNG ADULT;

EID: 84889992967     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.536     Document Type: Article

References (40)

1. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis 2010; 31: 100-110.
2. Finn RS. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Cancer Res 2010; 16: 390-397.
3. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9: 153-166.
4. Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, Lian Z. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002; 21: 2593-2604.
5. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med 2003; 3: 573-588.
6. Naka T, Toyota N, Kaneko T, Kaibara N. Protein expression of p53, p21WAF1, and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma. Anticancer Res 1998; 18: 555-564.
7. Qin LF, Ng IO. Exogenous expression of p21(WAF1/CIP1) exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. Cancer Lett 2001; 172: 7-15.
8. Matsuda Y. Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma. World J Gastroenterol 2008; 14: 1734-1740.
9. Lee J, Kim SS. The function of p27 KIP1 during tumor development. Exp Mol Med 2009; 41: 765-771.
10. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8: 253-267.
11. Zhou Q, He Q, Liang LJ. Expression of p27, cyclin E and cyclin A in hepatocellular carcinoma and its clinical significance. World J Gastroenterol 2003; 9: 2450-2454.
12. Nguyen H, Gitig DM, Koff A. Cell-free degradation of p27(kip1), a G1 cyclindependent kinase inhibitor, is dependent on CDK2 activity and the proteasome. Mol Cell Biol 1999; 19: 1190-1201.
13. Chen L, Yuan D, Wang GL, Wang Y, Wu YY, Zhu J. Clinicopathological significance of expression of Tspan-1, Jab1 and p27 in human hepatocellular carcinoma. J Korean Med Sci 2010; 25: 1438-1442.
14. Tannapfel A, Grund D, Katalinic A, Uhlmann D, Kockerling F, Haugwitz U et al. Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma. Int J Cancer 2000; 89: 350-355.
15. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-1512.
16. He G, Kuang J, Huang Z, Koomen J, Kobayashi R, Khokhar AR et al. Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21. Br J Cancer 2006; 95: 1514-1524.
17. Nan KJ, Jing Z, Gong L. Expression and altered subcellular localization of the cyclin-dependent kinase inhibitor p27Kip1 in hepatocellular carcinoma. World J Gastroenterol 2004; 10: 1425-1430.
18. Huang X, Qian X, Cheng C, He S, Sun L, Ke Q et al. Expression of Pirh2, a p27(Kip1) ubiquitin ligase, in hepatocellular carcinoma: correlation with p27(Kip1) and cell proliferation. Hum Pathol 2011; 42: 507-515.
19. Zhao Y, Tang Q, Ni R, Huang X, Wang Y, Lu C et al. Early mitotic inhibitor-1, an anaphase-promoting complex/cyclosome inhibitor, can control tumor cell proliferation in hepatocellular carcinoma: correlation with Skp2 stability and degradation of p27(Kip1). Hum Pathol 2012; 44: 365-373.
20. Cakmakci NG, Lerner RS, Wagner EJ, Zheng L, Marzluff WF. SLIP1, a factor required for activation of histone mRNA translation by the stem-loop binding protein. Mol Cell Biol 2008; 28: 1182-1194.
21. Gorgoni B, Andrews S, Schaller A, Schumperli D, Gray NK, Muller B. The stem-loop binding protein stimulates histone translation at an early step in the initiation pathway. RNA 2005; 11: 1030-1042.
22. Vervoorts J, Luscher B. Post-translational regulation of the tumor suppressor p27(KIP1). Cell Mol Life Sci 2008; 65: 3255-3264.
23. Pippa R, Espinosa L, Gundem G, Garcia-Escudero R, Dominguez A, Orlando S et al. p27Kip1 represses transcription by direct interaction with p130/E2F4 at the promoters of target genes. Oncogene 2012; 31: 4207-4220.
24. Pietras EM, Warr MR, Passegue E. Cell cycle regulation in hematopoietic stem cells. J Cell Biol 2011; 195: 709-720.
25. Greenbaum LE. Cell cycle regulation and hepatocarcinogenesis. Cancer Biol Ther 2004; 3: 1200-1207.
26. Andrisani OM, Studach L, Merle P. Gene signatures in hepatocellular carcinoma (HCC). Semin Cancer Biol 2011; 21: 4-9.
27. Qin J, Wang Z, Wang Y, Ma L, Ni Q, Ke J. JAB1 expression is associated with inverse expression of p27(kip1) in hepatocellular carcinoma. Hepatogastroenterology 2010; 57: 547-553.
28. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008; 27: 5651-5661.
29. Perez-Luna M, Aguasca M, Perearnau A, Serratosa J, Martinez-Balbas M, Jesus Pujol M et al. PCAF regulates the stability of the transcriptional regulator and cyclin-dependent kinase inhibitor p27Kip1. Nucleic Acids Res 2012; 40: 6520-6533.
30. Podust VN, Brownell JE, Gladysheva TB, Luo RS, Wang C, Coggins MB et al. A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination. Proc Natl Acad Sci USA 2000; 97: 4579-4584.
31. Nakamura S, Okinaka K, Hirano I, Ono T, Sugimoto Y, Shigeno K et al. KIS induces proliferation and the cell cycle progression through the phosphorylation of p27Kip1 in leukemia cells. Leuk Res 2008; 32: 1358-1365.
32. Motti ML, De Marco C, Califano D, Fusco A, Viglietto G. Akt-dependent T198 phosphorylation of cyclin-dependent kinase inhibitor p27kip1 in breast cancer. Cell Cycle 2004; 3: 1074-1080.
33. De Vita F, Riccardi M, Malanga D, Scrima M, De Marco C, Viglietto G. PKCdependent phosphorylation of p27 at T198 contributes to p27 stabilization and cell cycle arrest. Cell Cycle 2012; 11: 1583-1592.
34. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 1997; 11: 1464-1478.
35. Wu L, Fan J, Belasco JG. MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci USA 2006; 103: 4034-4039.
36. Bansal N, Zhang M, Bhaskar A, Itotia P, Lee E, Shlyakhtenko LS et al. Assembly of the SLIP1-SLBP complex on histone mRNA requires heterodimerization and sequential binding of SLBP followed by SLIP1. Biochemistry 2013; 52: 520-536.
37. Zhao X, McKillop-Smith S, Muller B. The human histone gene expression regulator HBP/SLBP is required for histone and DNA synthesis, cell cycle progression and cell proliferation in mitotic cells. J Cell Sci 2004; 117: 6043-6051.
38. Sullivan E, Santiago C, Parker ED, Dominski Z, Yang X, Lanzotti DJ et al. Drosophila stem loop binding protein coordinates accumulation of mature histone mRNA with cell cycle progression. Genes Dev 2001; 15: 173-187.
39. Narita T, Yung TM, Yamamoto J, Tsuboi Y, Tanabe H, Tanaka K et al. NELF interacts with CBC and participates in 3' end processing of replication-dependent histone mRNAs. Mol Cell 2007; 26: 349-365.
40. Ke Q, Ji J, Cheng C, Zhang Y, Lu M, Wang Y et al. Expression and prognostic role of Spy1 as a novel cell cycle protein in hepatocellular carcinoma. Exp Mol Pathol 2009; 87: 167-172.